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Abstract
Background: The clinical metrics used to date to assess the progression risk of newly
diagnosed prostate cancer patients only partly represent the true biological aggres-
siveness of the underlying disease.
Objective: Validation of the prognostic biomarker phosphodiesterase-4D7 (PDE4D7) in
predicting longitudinal biological outcomes in a historical surgery cohort to improve
postsurgical risk stratification.
Design, patients, and methods: RNA was extracted from biopsy punches of resected
tumors from 550 patients. PDE4D7 was quantified using one-step quantitative reverse
transcription-polymerase chain reaction. PDE4D7 scores were calculated by normaliza-
tion of PDE4D7 to reference genes. Multivariate analyses were adjusted for clinical
prognostic variables. Outcomes tested were: prostate-specific antigen relapse, start of
salvage treatment, progression to metastases, overall mortality, and prostate cancer-
specific mortality. The PDE4D7 score was combined with the clinical risk model Cancer
of the Prostate Risk Assessment Postsurgical Score (CAPRA-S) using multivariate regres-
sion modeling; the combined score was tested in post-treatment progression free
survival prediction.
Outcome measurements and statistical analysis: Correlations with outcomes were
analyzed using multivariate Cox regression and logistic regression statistics.
Results and limitations: The PDE4D7 score was significantly associated with time-to-
prostate specific antigen failure after prostatectomy (hazard ratio [HR]: 0.53, 95%
confidence interval [CI]: 0.41–0.67 for each unit increase, p < 0.0001). After adjustment
for postsurgical prognostic variables the HR was 0.56 (95% CI: 0.43–0.73, p < 0.0001).
The PDE4D7 score remained significant after adjusting the multi-variate analysis for thegor
th tCAPRA-S model cate
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surgery. The combined model of PDE4D7 and CAPRA-S improves patient selection with very
high risk of fast disease relapse after primary intervention.
Conclusions: The PDE4D7 score has the potential to provide independent risk information
and to restratify patients with clinical intermediate- to high-risk characteristics to a very
low-risk profile.
Patient summary: In this report, we studied the potential of a novel biomarker to predict
outcomes of a cohort of prostate cancer patients who underwent surgery more than 10 yr
ago. We found that a gene called phosphodiesterase-4D7 added extra information to the
available clinical data. We conclude that the measurement of this gene in tumor tissue may
contribute to more effective treatment decisions.
© 2017 European Association of Urology. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Prostate cancer displays as a heterogeneous disease with
varying potential to develop progressively to deadly forms
of the disease. Of the estimated 417 000 annual new cases in
Europe, around 92 000 will die from their disease [1].
Accurate risk stratification of prostate cancer patients is
essential to identify men who benefit from adjuvant or
multi-modality treatments while sparing those with low
risk from the adverse effects of aggressive therapy. Various
clinic metrics have been developed in the past to predict
disease progression after primary treatments such as sur-
gery or radiation therapy [2]. Typically, predictions are
based on the combination of clinical variables that are
available at the moment of clinical need. However, clinical
risk descriptors are limited by the information content of
their clinical input variables and do not necessarily describe
effectively either the extent of the disease or its aggres-
siveness for all patients [3–5]. Thus, there is a need for
better patient stratification in order to optimize disease
management. Additional molecular information represent-
ing the biology of the disease offers the potential to achieve
this [6].
The cyclic adenosine monophosphate (cAMP) signaling
pathway is known to play an important role in both the
development and progression of prostate cancer [7]. While
a family of adenylate cyclases is responsible for the synthe-
sis of cAMP, cyclic nucleotide phosphodiesterases (PDEs)
represent the only cellular mechanism for its destruction.
PDEs provide both signal termination and, importantly, the
compartmentalization of cAMP signaling within the three-
dimensional matrix of cells. This is achieved through the
spatially discrete destruction of cAMP via subpopulations of
distinct PDE isoforms sequestered by localized anchor pro-
teins/signalosomes [8–10]. Thus, changes in the expression
and/or activity of distinct PDE isoforms can alter down-
stream signaling pathways during disease development and
progression, providing potential targets for novel biomark-
ers and for targeted therapeutic intervention.
In this study, we demonstrate that PDE4D7 transcript
levels correlate to the longitudinal outcome of prostate
cancer after primary treatment. We further hypothesized
that PDE4D7 independently adds to clinical risk stratifica-
tion metrics like the Cancer of the Prostate Risk Assessment
Postsurgical (CAPRA-S) score [11], which may add value for
clinical decision-making.2. Patients and methods
2.1. Patient cohorts and samples
Two small adjacent biopsy punches (approximately 1  2 mm) of a
representative resected area of the largest volume tumor of 550 patients
operated on between 2000 and 2004 at Martini Klinik (Hamburg,
Germany) were collected (Table 1) with local Institutional Review Board
approval. Patients with adjuvant hormone therapy were removed from
the analysis. After data quality control based on predefined criteria,
503 patient samples were eligible for statistical analysis (Supplementary
Figs. 1 and 2). For independent validation purposes, we selected a
prostate cancer data set published previously [12]. All men with primary
prostate cancer with available postsurgical outcome data as well as
PDE4D7 expression data based on exon array measurements were
selected for the validation (n = 130; Table 1).
2.2. Laboratory methods
Quantitative real-time polymerase chain reaction (RT-qPCR) primers and
probes are outlined in Supplementary Table 1. RNA extraction, RT-qPCR
assay development and protocols are described in the Supplementary
data. The limit of detection for RT-qPCR quantification cycle value (Cq)
was determined and was used as a predefined quality threshold to
discard samples from the statistical analysis (Supplementary data).
2.3. Data analysis and statistics
Normalized PDE4D7 expression was calculated by subtracting the Cq of
the respective PDE4D transcript from the averaged Cq of the reference
genes [13] and transformed to the PDE4D7 score (Supplementary Fig. 3).
The CAPRA-S risk score and corresponding low- (1), intermediate- (2),
high-risk (3) categories were calculated as described previously
[11]. Uni- and multivariate Cox regression analysis and modeling was
applied to correlate biochemical recurrence progression free survival
(BCR PFS) to the PDE4D7 score in the study cohort (n = 503) and the
validation cohort (n = 130). The PDE4D7 score was either used as a
continuous or as a categorical variable. The multi-variate analyses were
adjusted for postsurgical clinical variables.
Logistic regression models to predict 2-yr or 5-yr BCR PFS were
created using the CAPRA-S categories and the continuous PDE4D7 score
as variables in the study cohort with complete 5-yr follow-up (-
n = 469 and n = 449, respectively). For statistical analysis, the software
packages MedCalc (MedCalc Software BVBA, Ostend, Belgium) or R (R
Foundation for Statistical Computing, Vienna, Austria) were used. All p
values are two-sided; statistical significance is based on alpha level
0.05.
Analysis of GSE21034 [12]: raw CEL files were downloaded from Gene
Expression Omnibus. Data processing and robust multichip average
Table 1 – Patient demographics of the analyzed patient surgery study and validation cohorts.
Parameter Study cohort
(n = 503)
Validation cohort
(n = 130)
Demographic & clinical characteristics,
range (median; IQR)
Age range 41.3–74.5 (62.6; 7.4) 37.3–83 (58.0; 8.7)
Preoperative PSA range 0.18–73.16 (6.7; 5.5) 1.15–46.4 (5.9; 4.6)
Percent tumor in biopsy range 0.2–79.7 (10.3; 16.0) NA
Prostate volume range 9–148 (42; 22.5) NA
PSA density range 0.18–73.2 (6.7; 5.5) NA
NCCN risk category, N (%) Very low risk 67 (13.3) 58 (44.6)
Low risk 144 (28.6)
Intermediate favorable risk 128 (25.4) 32 (24.6)
Intermediate unfavorable risk 120 (23.9) 21 (16.2)
High risk 44 (8.7) 19 (14.6)
Presurgery pathology, N (%) Biopsy Gleason 3 + 3 316 (62.8) 78 (60.0)
Biopsy Gleason 3 + 4 149 (29.6) 29 (22.3)
Biopsy Gleason 4 + 3 25 (5.0) 12 (9.2)
Biopsy Gleason 4 + 4 13 (2.6) 11 (8.5)
cT1 342 (68) 74 (56.9)
cT2 150 (29.8) 51 (39.2)
cT3 11 (2.2) 5 (3.8)
Postsurgery pathology, N (%) Pathology Gleason 3 + 3 201 (40) 42 (32.3)
Pathology Gleason 3 + 4 257 (51.1) 53 (40.8)
Pathology Gleason 4 + 3 41 (8.2) 21 (16.2)
Pathology Gleason 4 + 4 4 (0.8) 14 (10.8)
pT2 331 (65.8) 85 (65.4)
pT3 172 (34.2) 39 (30.0)
pT4 0 (0) 6 (4.6)
Positive surgical margins 120 (23.9) 29 (22.3)
Extracapsular extension (T3a) 113 (22.5) 87 (66.9)
Seminal vesicle invasion 60 (11.9) 13 (10.0)
Lymph node invasion 5 (1) 5 (3.7)
Follow-up, mo (IQR follow-up) Mean 123.6 58.2
Median 141.8 (60.1) 54.2 (35.6)
Outcome, no. of events/total patient no.
(percentage; follow-up; IQR)
BCR within 5 yr 92/446 (20.6; 121.2; 87.5) 26/130 (20.0; 46.9; 33.6)
BCR within 10 yr 134/347 (38.6; 134.0; 95.6)
CR within 5 yr 5/441 (1.1; 144.4; 37.8) 8/130 (6.2; 52.3; 34.9)
CR within 10 yr 13/306 (4.2; 154.7; 32.85)
Salvage treatment, no. events/total patient no.
(percentage; follow-up; IQR)
SRT within 5 yr 53/439 (12.1; 120.4; 53.5) 13/130 (10.0; NA; NA)
SRT within 10 yr 83/320 (25.9; 132.3; 39.6)
SADT within 5 yr 27/441 (6.1; 120.7; 46.6) 14/130 (10.8; NA; NA)
SADT within 10 yr 54/312 (17.3; 132.4; 24.2)
Survival, no. events/total patient no.
(percentage; follow-up; IQR)
PCSM within 5 yr 17/453 (1.1; 144.4; 37.7) 0/130 (0; NA; NA)
PCSM within 10 yr 38/330 (2.6; 154.8; 30.3)
OM within 5 yr 5/441 (3.7; 144.4; 45.1) NA
OM within 10 yr 10/302 (11.2; 146.0; 35.4)
BCR = biochemical recurrence; CR = clinical recurrence; IQR = interquartile range; OM = overall mortality; NA = not applicable; PCSM = prostate cancer-specific
mortality; PSA = prostate-specific antigen; SADT = salvage androgen deprivation therapy; SRT = salvage radiotherapy.
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(Affymetrix Inc, CA, USA) [14] and transcript expression was measured by
averaging log2-transformed intensity values of the following isoform-
specific probe sets: PDE4D7 (2858406, 2858407, and 2858408). The
normalized PDE4D7 expression values were transformed into a PDE4D7
score equivalent to the qPCR expression data.
3. Results
3.1. Correlation of PDE4D7 score to longitudinal clinical
outcomes
We set out to correlate the expression of the putative
prostate cancer biomarker PDE4D7, which has recently beeninitially described by us [13], to the longitudinal patient
outcome of BCR after surgery. Although prostate-specific
antigen (PSA) relapse is regarded as a surrogate for more
severe clinical outcomes like metastases or cancer-specific
death, it is nevertheless very often used as a trigger to start
secondary treatments.
Univariate and multi-variate Cox regression analysis
demonstrated a significant correlation of the continuous
PDE4D7 score to time to BCR (hazard ratio: 0.53, 95%
confidence interval [CI]: 0.41–0.67, p < 0.0001, and hazard
ratio: 0.56, 95% CI: 0.43–0.73, p  0.0001, respectively;
Table 2, Supplementary Fig. 4A). Adjusting the multi-variate
Cox regression analysis for the prognostic CAPRA-S score
resulted in a significant independent contribution to the
Table 4 – Uni- and multi-variate Cox regression analysis of the biochemical recurrence (BCR) free survival of the phosphodiesterase-4D7
(PDE4D7) score categories in the patient surgery cohort adjusted for the Cancer of the Prostate Risk Assessment Postsurgical Score (CAPRA-S)
in the study cohort (n = 503).
Postsurgical clinical parameters Uni-variate (enter) Multi-variate (enter)
Endpoint BCR (#503/#148; 29.4%) p value HR 95% CI of HR p value HR 95% CI of HR
CAPRA-S score category (1; n = 288); reference
CAPRA-S score category (2; n = 173) <0.0001 2.9 2.0–4.2 <0.0001 2.9 2.0–4.2
CAPRA-S score category (3; n = 42) <0.0001 8.7 5.5–13.7 <0.0001 8.2 5.2–13.1
PDE4D7 score (4–5; n = 85); reference
PDE4D7 score (3–4; n = 289) 0.02 2.1 1.1–3.8 0.02 2.1 1.2–3.9
PDE4D7 score (2–3; n = 118) <0.0001 3.8 2.0–7.1 0.0001 3.5 1.8–6.5
PDE4D7 score (1–2; n = 11) 0.0005 5.7 2.1–15.2 0.0007 5.5 2.1–14.7
CI = confidence interval; HR = hazard ratio.
Table 2 – Uni- and multivariate Cox regression analysis of the biochemical recurrence (BCR) free survival of the phosphodiesterase-4D7
(PDE4D7) score in the patient surgery cohort adjusted for postsurgical clinical variables in the study cohort (n = 503).
Postsurgical clinical parameters Uni-variate Multi-variate
Endpoint BCR (#503/#148; 29.4%) p value HR 95% CI of HR p value HR 95% CI of HR
Pathology Gleason score 3 + 3 (n = 201); reference
Pathology Gleason score 3 + 4 (n = 257) 0.003 2.10 1.4–3.1 0.24 0.77 0.5–1.2
Pathology Gleason score 4 + 3 (n = 41) <0.0001 8.60 5.2–14.2 <0.0001 2.6 1.7–4.2
Pathology Gleason score 4 + 4 (n = 4) <0.0001 27.7 9.7–79.2 <0.0001 13.3 4.5–39.4
Pathology Stage pT2 (n = 331); reference
Pathology Stage pT3 (n = 172) <0.0001 4.30 3.1–6.0 0.0001 2.4 1.6–3.6
Surgical margin status <0.0001 2.60 1.8–3.6 0.0006 1.0 1.3–2.7
Seminal vesicle invasion <0.0001 4.50 3.1–6.4 0.027 1.6 1.1–2.5
Lymph node invasion <0.0001 55.7 20.9–148.6 0.0015 5.5 1.9–15.6
PDE4D7 score (continuous) <0.0001 0.53 0.41–0.67 <0.0001 0.56 0.43–0.73
CI = confidence interval; HR = hazard ratio.
Table 3 – Uni- and multi-variate Cox regression analysis of the biochemical recurrence (BCR) free survival of the phosphodiesterase-4D7
(PDE4D7) score in the patient surgery cohort adjusted for the Cancer of the Prostate Risk Assessment Postsurgical Score (CAPRA-S) in the
study cohort (n = 503).
Postsurgical clinical parameters Uni-variate (enter) Multi-variate (enter)
Endpoint BCR (#503/#148; 29.4%) p value HR 95% CI of HR p value HR 95% CI of HR
CAPRA-S score category (1; n = 288); reference
CAPRA-S score category (2; n = 173) <0.0001 2.9 2.0–4.2 <0.0001 2.9 2.0–4.2
CAPRA-S score category (3; n = 42) <0.0001 8.7 5.5–13.7 <0.0001 8.4 5.3–13.3
PDE4D7 (continuous) <0.0001 0.53 0.41–0.67 <0.0001 0.54 0.42–0.69
CI = confidence interval; HR = hazard ratio.
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the categorical PDE4D7 score (Tables 3 and 4, Supplemen-
tary Figs. 4B and 4C).
Next, we investigated the hazard of biochemical progres-
sion across the continuous PDE4D7 score (Fig. 1A). It is
evident that patients with the highest PDE4D7 scores (>4)
demonstrated virtually no risk of postsurgical progression.
We observed a linear increase of the hazard between
PDE4D7 scores 2–5 while a steep increase occurred when
the PDE4D7 scores decreases below a value of 2. Although
the number of men in this lowest PDE4D7 score category (1–
2) is small (n = 11) it seems that this group of men harbor a
distinct form of prostate cancer as their risk clearly deviates
from the observed linear increase of any PDE4D7 score >2.Kaplan-Meier analysis revealed that the PDE4D7 score
category (4–5) includes men with a <5% probability of 5-yr
BCR while the chance to experience this endpoint increased
to >50% for patients in PDE4D7 score category (1–2) with all
events occurring within 3.5 yr after surgery (logrank
p < 0.0001; Fig. 1B, Supplementary Table 4).
When comparing the patient characteristics of the vali-
dation population to the study cohort (Table 1) we noticed a
similar distribution of clinical risks for the low- (41.9% vs
44.6%, p = 0.73) and intermediate favorable-risk groups
(25.4% vs 24.6%, p = 0.91) in both cohorts while there is a
nonsignificant trend towards less unfavorable intermedi-
ate-risk (16.2% vs 23.9%, p = 0.16) but more high-risk cases
(8.7% vs 14.6%, p = 0.08) in the study versus the validation
Fig. 1 – (A) Regression terms for the phosphodiesterase-4D7 (PDE4D7)
scores calculated from Cox proportional hazard model predicting
biochemical recurrence (BCR) free survival in the study cohort (n = 503).
(B) Kaplan-Meier analysis of the PDE4D7 score with BCR free survival in
the study cohort (n = 503). (C) Kaplan-Meier analysis of the PDE4D7
score with BCR free survival in the in the validation cohort (n = 130).
Fig. 2 – (A) Receiver operating characteristic cuve analysis of 2-yr
biochemical recurrence for the incremental value of the
phosphodiesterase-4D7 (PDE4D7) score added to the Cancer of the
Prostate Risk Assessment Postsurgical Score (CAPRA-S) categories by
logistic regression analysis in the study cohort (n = 469). (B) Receiver
operating characteristic cuve analysis of 5-yr biochemical recurrence for
the incremental value of the PDE4D7 score added to the CAPRA-S score
categories by logistic regression analysis in the study cohort (n = 449).
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the four PDE4D7 score categories with BCR PFS showed very
similar results as found in the study cohort (logrank
p = 0.036; Fig. 1C, Supplementary Table 5).Testing of other clinical endpoints other than BCR dem-
onstrated equivalent association of PDE4D7 in the Cox
regression analysis (Supplementary Fig. 4D, Supplementary
Table 3).
3.2. Outcome modeling of combined clinical and PDE4D7 score
categories
The data presented here indicate that the risk of disease
progression provided by PDE4D7 scores offers a novel
Fig. 3 – Analysis of 5-yr biochemical recurrence free survival predicted by a logistic regression model of the Cancer of the Prostate Risk Assessment
Postsurgical Score (CAPRA-S) categories and the phosphodiesterase-4D7 (PDE4D7) scores in a patient subcohort with complete 5-yr follow-up in the
study cohort (n = 449). CAPRA-S (1) = CAPRA-S Scores 0–2; CAPRA-S (2) = CAPRA-S Scores 3–5; CAPRA-S (3) = CAPRA-S Scores 6.
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to be complementary to the risks provided by clinical
practice criteria. Thus, we hypothesized that the combina-
tion with clinical risk scores by computational modeling
might predict long-term disease outcomes more effectively
compared with using any single score alone. To evaluate this
hypothesis, we selected a subcohort of 449 patients
(92 events; 20.5%) with complete 5-yr outcome histories
and generated a logistic regression model to combine the
established clinical metric of the CAPRA-S score categories
with the PDE4D7 score in order to predict the 5-yr risk of
BCR after surgery. The modeling proved the independent
predictive value of the PDE4D7 scores (odds ratio: 0.45, 95%
CI: 0.29–0.67, p = 0.0001; data not shown). Receiver oper-
ating characteristic analysis calculated the 2-yr, 5-yr area
under the curves (AUC) as 0.82 and 0.78, respectively. The
PDE4D7 score showed incremental value to the AUC of
CAPRA-S categories alone of 6% (p = 0.0004) and 4%
(p = 0.003) to the 2-yr and 5-yr postsurgical progression
prediction, respectively (Fig. 2A and 2B). Cross-validation of
the logistic regression model in the validation cohort
showed AUCs of 0.77 and 0.74 for the 2-yr and 5-yr outcome
prediction, respectively. The logit function of the regression
model was used to predict the individual 5-yr BCR PFS.
Predicted risk analysis per clinical risk group as a function of
PDE4D7 scores revealed heterogeneous 5-yr progression
risk distribution even within the lowest CAPRA-S risk cate-
gory (Fig. 3).
To evaluate this further we modeled the probability of
BCR in the study cohort after surgery by Cox regressionusing the CAPRA-S risk categories as well as the continuous
PDE4D7 score as inputs. The regression function was used
to calculate the probability of biochemical progression
after surgery for the patient study cohort. Based on the
progression probability we defined four risk groups of PSA
failure and compared this with survival prediction of the
CAPRA-S score categories alone (Fig. 4A and 4B). When
using probability group (0 to <0.1) as a reference in the
Kaplan-Meier analysis the hazard ratios for probability
groups (0.1 to <0.25), (0.25 to <0.5), and (0.5–1.0) were
2.0 (95% CI: 1.4–2.9), 5.7 (95% CI: 3.5–9.1), and 17.2 (95% CI:
6.0–49.2) compared with hazard ratios of 2.9 (95% CI: 2.0–
4.1) and 8.4 (95% CI: 3.9–17.8) for the CARPA-S score
category model (Supplementary Tables 6 and 7). We tested
the CAPRA-S and PDE4D7 Cox regression model in the
validation cohort to confirm that the four probability
groups represent patient cohorts with significant differ-
ence in postsurgical risk of disease progression (Fig. 4C,
Supplementary Table 8). We finally applied Kaplan-Meier
survival analysis to demonstrate the ability of PDE4D7 to
restratify the risk in particular the CAPRA-S (2) and (3)
patients into groups of patients with high BCR PFS (>70%)
versus those with low BCR PFS (<20%; Supplementary
Table 10).
We have illustrated that the measurement of the pros-
tate cancer biomarker PDE4D7 in a tumor sample provides
risk stratification information to predict long-term clinical
outcomes. Moreover, PDE4D7 provided independent and
incremental value to the existing risk prediction algorithm
CAPRA-S.
Fig. 4 – (A) Kaplan-Meier analysis of the biochemical recurrence (BCR)
free survival predicted by the Cancer of the Prostate Risk Assessment
Postsurgical Score (CAPRA-S) categories in the study cohort (n = 503). (B)
Kaplan-Meier analysis of the BCR free survival predicted by a Cox regression
model of the CAPRA-S categories and the phosphodiesterase-4D7 (PDE4D7)
score in the study cohort (n = 503). (C) Kaplan-Meier analysis of the BCR
free survival predicted by a Cox regression model of the CAPRA-S categories
and the PDE4D7 score in the validation cohort (n = 130).
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The management of prostate cancer patients is strongly
dependent on risk profiling. Several risk metrics based onclinical inputs have been developed to predict either before
or after surgery the risk of PSA progression [2]. Cooperberg
and colleagues [11] presented the postsurgical prediction
algorithm, CAPRA-S, which is based on a weighted sum of
scores for the clinical variables preoperative PSA, pathology
Gleason score, pathology status of extracapsular extension,
seminal vesicle invasion, surgical margins, and lymph node
invasion. The resulting CAPRA-S score is categorized into
three groups representing low- (CAPRA-S 0–2), intermedi-
ate- (CARPA-S 3–5), and high- (CAPRA-S  6) risk of disease
progression after surgery. The c-index was initially reported
to be 0.77 for 5-yr BCR PFS [11]. In a large validation study
using external data, a c-index of 0.73 for the prediction of
BCR at 5 yr after surgery was published [15]. The CAPRA-S
score is one of the most extensively validated clinical risk
metric.
Alterations in the expression of members of the cAMP-
degrading PDE4 family are associated with several diseases,
including stroke [16], acrodysostosis [17,18], schizophrenia
[19], and chronic obstructive pulmonary disease [20]. Func-
tionally, PDE4D provides part of the cellular desensitization
system to cAMP and enables cross-talk between signaling
pathways that lead to the activation of extracellular signal-
regulated kinase and AMP-activated protein kinase [21], for
example. Recently, we have shown that down-regulation of
a particular PDE4 isoform (PDE4D7) may impact on prostate
cancer [13,22,23].
Therefore, we investigated the incremental value of
PDE4D7 to CAPRA-S to predict postsurgical PSA relapse.
To test this, we generated logistic and Cox regression
models for BCR PFS to combine the CAPRA-S categorical
score with the continuous PDE4D7 score. Both regression
models showed better performance in predicting fast
relapse within 24 mo after the primary treatment. The
incremental value of PDE4D7 to the CARPA-S was larger
in this setting compared with the 5-yr outcome prediction
(6% vs 4%, respectively); however, in both settings the
incremental contribution of the PDE4D7 score was statisti-
cally significant.
Testing the PDE4D7 score in Cox regression modeling
with CAPRA-S to model time-to-PSA recurrence indicated
the impact of PDE4D7 for patients at high risk of postsurgi-
cal PSA relapse within 24–36 mo after operation. The
Kaplan-Meier analysis showed that patients with the high-
est probability of relapse after surgery had a mean PFS of
44.6 mo when stratified with the CAPRA-S and PDE4D7
combined score versus 64.3 mo for the CARPA-S model
alone.
Not all patients with PSA failure after local therapy have
the same prognostic pathway in terms of future disease
progression. Fast PSA doubling times and fast PSA recur-
rence after surgery have been significantly associated with
progression to metastases and prostate cancer-specific mor-
tality [24]. In our study cohort, we confirmed the correlation
between the mean time to BCR and prostate cancer-specific
death. The mean BCR PFS of 44.6 mo in the highest CAPRA-S
and PDE4D7 risk group corresponds to a 22.2% risk of
prostate cancer specific in this cohort. In contrast to a risk
of 11.9% to die from prostate cancer in the CAPRA-S category
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data support the view that lowest level of PDE4D7 scores
contribute to higher risk of rapid recurrence after primary
intervention. Several retrospective studies have provided
evidence that stratification of patients to salvage radiation
therapy after local failure based on time-to-PSA recurrence
may increase cancer-specific survival [25,26]. Thus, accu-
rate stratification of patients is essential to provide most
optimal therapeutic strategies for patients.
Our study is limited by the retrospective design. Due to
the long-term follow-up of 10–15 yr as well as the chosen
design to investigate a consecutively managed patient
cohort the clinical risk distribution may not completely
represent the risk of a contemporary surgery cohort. The
study population includes a limited number of high-risk
cases which may limit the generalizability of our presented
results to high-risk populations. This is important to note as
one of our main findings is that PDE4D7might support
improved stratification of patients at high risk of post-
surgical disease recurrence. Thus, PDE4D7 may have a role
in the selection of secondary treatments for this patient
group. However, to confirm this further research in clini-
cally high-risk patient cohorts is required.
5. Conclusions
We have validated the prostate cancer biomarker PDE4D7 in
a historic patient cohort consecutively managed by radical
prostatectomy. We confirmed the independent prognostic
and incremental value of PDE4D7 score next to the estab-
lished clinical risk metric CAPRA-S score. The PDE4D7 score
may support the risk stratification of patients after local
treatment to select the right timing for the start of second-
ary therapy for men at very high-risk of rapid disease
recurrence.
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